CytoDyn closes $16.5 million financing to fund leronlimab development
CytoDyn says it has closed a $16.5 million financing to fund continued development of leronlimab, its humanized monoclonal antibody targeting the CCR5 receptor.
VANCOUVER, Washington, Sept.
01, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc.
OTCQB:CYDY("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, i…